U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer ...

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

After its success in treating blood cancers: CAR-T Therapy is now purposed to treat autoimmune disease, Lupus. -p -p ...

Presbyterian Healthcare Services recently unveiled the HALL, a 25,200-square-foot learning lab dedicated to giving health care workers a space to learn new skills while enhancing old skills. The $6 ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...

Officially Benefiting Mainland China PatientsSHANGHAI, Dec 18, 2024 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, ...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

REGIONS NEWS Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially ...

Xentria, Inc. (Xentria), a clinical-stage biotherapeutics company focused on advancing drug development to address unmet medical needs, today announced it has entered into an exclusive license ...

Dr. Josh Landers has been named chair and assistant professor of Biomedical Sciences at the Lyon College School of Dental ...